ICUI

ICU MEDICAL INC/DE

7 filings tracked

healthcaremedical devicesMID ($2B-10B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion

90%

bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat

70%

neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture

60%

bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure

50%

bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action

80%

bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion

90%

bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat

70%

neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture

60%

bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure

50%

bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action

80%

bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion

90%

bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat

70%

neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture

60%

bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure

50%

bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action

80%

bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion

90%

bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat

70%

neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture

60%

bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure

50%

bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action

80%

bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion

90%

bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat

70%

neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture

60%

bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure

50%

bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action

80%

bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion

90%

bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat

70%

neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture

60%

bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure

50%

bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action

80%

bullishMay 7

Gross margins increased from 34.8% to 38.9% following the divestiture of low-margin IV fluids.

margin expansion

90%

bullishMay 7

Net income swung to a $30.1M profit from a $15.5M loss in the prior year period.

earnings beat

70%

neutralMay 7

Sold 60% interest in IV Solutions business to OPF to focus on higher-margin segments.

divestiture

60%

bullishMay 7

Refinanced credit facilities and used $200M from divestiture to pay down Term Loan A.

debt restructure

50%

bearishMay 7

Ongoing risk from 2025 FDA Warning Letter regarding MedFusion and CADD pumps.

regulatory action

80%

Filing History

10-QMay 7, 2026

The Q1 2026 filing depicts a company in the midst of a high-stakes identity shift. By shedding the low-margin IV fluids business, ICU Medical has successfully engineered a rapid improvement in gross margins and a return to profitability, reporting net income of $30.1 million compared to a loss in the prior year. However, this financial recovery is partially skewed by a $29.2 million one-time tax benefit and the immediate impact of a major asset sale, masking the underlying decline in total top-line revenue. Investors are now weighing the benefit of a cleaner, higher-margin business model against the risks of extreme product concentration and lingering regulatory uncertainty. While the debt reduction and new product clearances provide a bullish foundation, the unresolved FDA issues and the pressure of a $1.26 billion debt load create a volatile risk profile. The ultimate success of the turnaround depends on whether the Plum precision pump platform can scale fast enough to offset the loss of the IV Solutions revenue and satisfy the company's heavy financial obligations.